KNSA Short Volume
Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Healthcare sector, specifically the Medical - Pharmaceuticals industry, with a market capitalization near $4.45B, listed on NASDAQ, employing roughly 366 people, carrying a beta of 0.12 to the broader market. Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. Led by Sanj K. Patel, public since 2018-05-24.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-06-30
- Short Volume
- 219.2K
- Total Volume
- 352.5K
- Short %
- 62.18%
- 30-Day Avg Short %
- 50.21%
Showing 30 days of FINRA short volume data for Kiniksa Pharmaceuticals International, plc.
Learn how short volume is reported and how to read the data →
Frequently asked KNSA short volume questions
- What is the daily KNSA short volume?
- As of Jun 30, 2026, Kiniksa Pharmaceuticals International, plc (KNSA) short volume is 219.2K shares against 352.5K total reported volume, or 62.18% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is KNSA short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does KNSA short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.